Clostridium perfringens beta-toxin (CPB)

Clostridium perfringens beta-toxin (CPB) is a highly potent, pore-forming exotoxin and the primary virulence determinant of Clostridium perfringens type C. It is responsible for causing severe necrotic enteritis and enterotoxemia in humans and livestock, particularly neonatal animals. The toxin acts by binding to the host cell receptor PECAM-1 (CD31) on endothelial and leukocytic cells, where it forms oligomeric pores that disrupt membrane integrity. This process leads to cell lysis, vascular damage, and extensive tissue necrosis in the small intestine. In humans, CPB is the causative agent of enteritis necroticans, also known as "Pigbel," which is characterized by high mortality rates. Therapeutic strategies focus on the administration of specific antitoxins to neutralize the toxin and the use of toxoid vaccines to induce protective immunity. However, the rapid progression of the disease often limits the effectiveness of treatment, and the use of animal-derived antitoxins can pose risks of hypersensitivity reactions. The target name provided, "Clostridium perfringens type C," refers to the bacterial strain rather than the specific molecular toxin.

Other names

Beta-toxinCPBClostridium perfringens type CC. perfringens type CClostridium perfringens type C beta-toxin

Neutralization of the toxin by specific antibodies to prevent pore formation and subsequent cell lysis.